Roth Capital Lowers Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED - Free Report) - Equities researchers at Roth Capital lowered their Q1 2025 earnings per share (EPS) estimates for shares of Globus Medical in a report issued on Thursday, March 13th. Roth Capital analyst J. Wittes now expects that the medical device company will post earnings per share of $0.71 for the quarter, down from their previous forecast of $0.74. The consensus estimate for Globus Medical's current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical's Q4 2025 earnings at $1.01 EPS.

A number of other research analysts have also recently commented on the company. StockNews.com upgraded Globus Medical from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Morgan Stanley upgraded Globus Medical from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $83.00 to $100.00 in a research report on Monday, December 2nd. Roth Mkm raised their price target on Globus Medical from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday, December 17th. Stifel Nicolaus raised their price target on Globus Medical from $92.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Bank of America upgraded Globus Medical from an "underperform" rating to a "neutral" rating and raised their price target for the stock from $80.00 to $97.00 in a research report on Thursday, January 9th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Globus Medical has a consensus rating of "Moderate Buy" and a consensus target price of $97.09.

Remove Ads

Globus Medical Stock Down 0.7 %

Shares of GMED traded down $0.52 during midday trading on Friday, reaching $71.63. 1,097,107 shares of the stock were exchanged, compared to its average volume of 987,869. Globus Medical has a twelve month low of $49.33 and a twelve month high of $94.93. The company has a market cap of $9.85 billion, a P/E ratio of 95.50, a PEG ratio of 1.61 and a beta of 1.19. The stock's 50 day simple moving average is $84.63 and its 200 day simple moving average is $79.80.

Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.10. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. The company had revenue of $657.29 million during the quarter, compared to the consensus estimate of $646.19 million.

Insider Activity

In related news, CFO Keith W. Pfeil sold 14,167 shares of Globus Medical stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $88.29, for a total value of $1,250,804.43. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 18.54% of the company's stock.

Hedge Funds Weigh In On Globus Medical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Oak Thistle LLC acquired a new position in shares of Globus Medical in the fourth quarter worth approximately $376,000. bLong Financial LLC acquired a new position in Globus Medical in the fourth quarter valued at approximately $397,000. Kathmere Capital Management LLC acquired a new position in Globus Medical in the fourth quarter valued at approximately $23,091,000. Intech Investment Management LLC lifted its stake in Globus Medical by 291.3% in the third quarter. Intech Investment Management LLC now owns 20,530 shares of the medical device company's stock valued at $1,469,000 after buying an additional 15,283 shares during the period. Finally, Quest Partners LLC acquired a new position in Globus Medical in the third quarter valued at approximately $523,000. 95.16% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.